Prof. Dr. Joachim Mittendorf ist Honorarprofessor an der Universität Leipzig und bringt als seine Expertise auf dem Feld der medizinischen Chemie an das Institut für organische Chemie.
Curriculum Vitae
- 1982 – 1987
Studium und Abschluss in Chemie an der Universität Göttingen - 1987 – 1989
Dissertation bei Prof. Dr. U. Schöllkopf im Fach Organische Chemie an der Universität Göttingen, gefördert durch ein Stipendium des Verbandes der Chemischen Industrie: „Eine neuartige Ringerweiterung von Dihydropyrazinen und Benzodihydroaromaten” - 1989 – 1990
Postdoc-Forschung bei Prof. K.P.C. Vollhardt an der University of California, Berkeley mit einem Feodor-Lynen-Stipendium der Alexander von Humboldt-Stiftung - 1990 – 1994
Senior Scientist in der Medizinischen Chemie bei der Bayer AG, Wuppertal; Forschungsgebiete: Antimykotika (ß-Aminosäuren), Virologie (HIV-Proteaseinhibitoren) - 1994 – 1996
Senior Scientist in der Pharma-Prozessentwicklung bei der Bayer AG, Wuppertal: Enantiomerenreine Dihydropyridine und ß-Aminosäuren - 1996 – 1999
Senior Scientist in der Medizinischen Chemie bei der Bayer AG, Wuppertal; Forschungsgebiete: ZNS (Neuroprotektiva zur Behandlung von Schlaganfall und Schädel-Hirn-Trauma), Asthma (Tryptase-Inhibitoren), Herz-Kreislauf-Erkrankungen (Koronare Herzkrankheit, Hämatologie) - 1999 – Okt. 2024
Direktor und seit 2016 VP der Medizinischen Chemie 2 bei der Bayer Pharma AG, Wuppertal; verantwortlich für Herzerkrankungen - 2002 – 2016
Projektleiter der Bayer Pharma-Forschungs-IT-Plattform „Pharmacophore Informatics” - seit Januar 2009
Honorarprofessor für Medizinische Chemie, Universität Leipzig, Deutschland - 2010 – 2024
Vorsitzender/ stellvertretender Vorsitzender der GDCH-Sektion Wuppertal-Hagen 2015 – 2019
Experte für medizinische Chemie im Nexavar-Rechtsstreit in Indien, einschließlich mehrerer Kreuzverhöre vor dem Delhi High Court
2020 – Oct 2024
Ko-Vorsitzender des Drug Delivery Council bei Bayer Pharmaceuticals R&D
- Mittendorf, J. Liebigs Ann. Chem. 1988, 1201:
Enantioselective synthesis of (R)- and (S)- 4-methylcycloserine by the bislactim ether method. - Schöllkopf, U.; Mittendorf, J. Angew. Chem. 1989, 101, 633:
From 2,5-dihydropyrazines to 2H-1,4-diazepines, and from benzodihydroarenes to benzocycloheptene derivatives, structural variants of the antidepressant protriptylene. - Hartwig, W.; Mittendorf, J. Synthesis 1991, 939:
Enantioselective synthesis of 2,3-diamino acids by the bislactim ether method. - Boese, R.; Green, J. R.; Mittendorf, J.; Mohler, D. L.; Vollhardt, K. P. C.: Angew. Chem. 1992, 104, 1643:
The first hexabutadiynylbenzene derivative: synthesis and structure. - Schmidt, U.; Schumacher, A.; Mittendorf, J.; Riedl, B. Journal of Peptide Research 1998, 52, 143:
Contribution to the synthesis of aureobasidin A. Synthesis of cyclopeptolides containing the sequence leucyl-N-methyl- -hydroxyvalyl-(2R)-oxy-(3R)-methyl-pentanoic acid. - Hartwig, W.; Mittendorf, J Encyclopedia of Reagents for Organic Synthesis 2001:
(2S)-(+)-2,5-Dihydro-2-isopropyl-3,6-dimethoxypyrazine. - Mauler, F.; Mittendorf, J.; Horváth, E.; De Vry, J. Journal of Pharmacology and Experimental Therapeutics 2002, 302, 359:
Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4-4-4-trifluoro-1-sulfonate (BAY 37-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. - Steinhagen, H.; Gerisch, M.; Mittendorf, J.; Schlemmer, K.-H.; Albrecht, B. Biorg. Med. Chem. Lett. 2002, 12, 3187 :
Substituted uracil derivatives as potent inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). - Mittendorf, J: Benet-Buchholz, J.; Fey, P. Mohrs, K.-H. Synthesis 2003, 136:
Efficient asymmetric synthesis of -amino acid BAY 10-8888 / PLD-118, a novel antifungal for the treatment of yeast infections. - Mittendorf, J; Kunisch, F.; Matzke, M.; Militzer, H.-C.; Schmidt, A.; Schoenfeld, W. Biorg. Med. Chem. Lett. 2003, 13, 433:
Novel antifungal -amino acids: Synthesis and activity against Candida albicans. - Kuhl A; Hahn M G; Dumic M; Mittendorf J. Amino Acids 2005, 29, 89:
Alicyclic beta-amino acids in Medicinal Chemistry. - Hasenoehrl A.; Galic T.; Ergovic G.; Marsic N.; Skerlev M.; Mittendorf J.; Geschke U.; Schmidt A.; Schoenfeld W. Antimicrobial agents and chemotherapy 2006, 50, 3011:
In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans. - Kast R; Schirok H; Figueroa-Perez S; Mittendorf J; Gnoth M J; Apeler H; Lenz J; Franz J K; Knorr A; Hutter J; Lobell M; Zimmermann K; Munter K; Augstein K H; Ehmke H; Stasch J P British Journal of Pharmacology 2007, 152, 1070:
Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase. - Schermuly R.; Stasch J.-P.; Pullamsetti S. S.; Middendorff R.; Mueller D.; Schlüter K.-D.; Dingendorf A.; Kolosionek E.; Kaulen C.; Dumitrascu R.; Weissmann N.; Mittendorf J.; Klepetko W.; Seeger W.;, Ghofrani H. A.; Grimminger F. Eur. Respir. J. 2008, 32, 881-891:
Expression and Function of Soluble Guanylate Cyclase in Pulmonary Arterial Hypertension. - Schirok, H.; Kast, R.; Figueroa-Perez, S.; Bennabi, S.; Gnoth, M. J.; Feurer, A.; Heckroth, H.; Thutewohl, M.; Paulsen, H.; Knorr, A.; Huetter, J.; Lobell, M.; Muenter, K.; Geiss, V.; Ehmke, H.; Lang, D.; Radtke, M.; Mittendorf, J.; Stasch, J.-P. ChemMedChem 2008, 3, 1893-1904:
Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors. - Mittendorf, J.; Weigand S.; Alonso-Alija C.; Bischoff E.; Feurer A.; Gerisch M.; Kern A.; Knorr A.; Lang D.; Muenter K.; Radtke M.; Schirok H.; Schlemmer K.-H.; Stahl, E.; Straub A.; Wunder F.; Stasch J.-P. ChemMedChem2009, 4, 853-865.
- Baerfacker L.; Kuhl A.; Hillisch A.; Grosser R.; Figueroa-Pérez S.; Heckroth H.; Nitsche A.; Ergueden J.-K.; Gielen-Haertwig H.; Schlemmer K.-H.; Mittendorf, J.; Paulsen H.; Platzek J.; Kolkhof P. ChemMedChem2012, 7, 1385-1403: Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases.
- Griebenow N.; Schirok H.; Mittendorf J.; Straub A.; Follmann M.; Stasch J.-P.; Knorr A.; Schlemmer K.-H.; Redlich G. Biorg. Med. Chem. Lett. 2013,23, 1197-2000: Identification of acidic heterocycle-substituted 1H-pyrazolo[3,4-b]pyridines as soluble guanylate cyclase stimulators.
- Follmann M.; Griebenow N.; Hahn M. G.; Hartung J.; Mais F.-J.; Mittendorf J.; Schaefer M.; Schirok H. Stasch J.-P., Stoll F.; Straub A. Angew. Chem. Int. Ed. 2013, 52, 9442-9462: The Chemistry and Biology of Soluble Guanylate Cyclase Stimulators and Activators.
- Nussbaum, F.; Li, V. M.-J.; Allerheiligen, S.; Anlauf, S.; Baerfacker, L.; Bechem, M.; Delbeck, M.; Fitzgerald, M. F.; Gerisch, M.; Gielen-Haertwig, H.; Haning, H.; Karthaus, D.; Lang, D.; Lustig, K.; Meibom, D.; Mittendorf, J.; Rosentreter, U.; Schaefer, M.; Schaefer, S.; Schamberger, J.; Telan, L. A.; Tersteegen, A. ChemMedChem 2015, 10, 1163-1173: Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases.
- Nussbaum, F.; Li, V. M.-J.; Meibom D.; Anlauf, S.; Bechem M.; Delbeck, M.; Gerisch, M.;Harrenga A.; Karthaus, D.; Lang, D.; Lustig, K.; Mittendorf, J.; Schaefer, M.; Schaefer, S.; Schamberger, J. ChemMedChem 2016, 11, 199-206: Potent and Selective Human Neutrophil Elastase Inhibitors with Novel Equatorial Ring Topology: in vivo Efficacy of the Polar Pyrimidopyridazine BAY-8040 in a Pulmonary Arterial Hypertension Rat Model
- Meibom D.; Albrecht-Kuepper B.; Diedrichs N.; Huebsch W.; Kast R.; Kraemer T.; Krenz U.; Lerchen H.-G.; Mittendorf J.; Nell P. G.; Suessmeier F.; Vakalopoulos A.; Zimmermann K. ChemMedChem 2017, 12, 728-737: Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist for the Chronic Treatment of Heart Diseases.
- Follmann M.; Ackerstaff J.; Redlich G.; Wunder F.; Lang D.; Kern A.; Griebenow N.; Kroh W.; Becker-Pelster E.-M.; Kretschmer A.; Geiss V.; Li V.; Straub A.; Mittendorf J.; Jautelat R.; Schirok H.; Schlemmer K.-H.; Lustig K.; Gerisch M.; Knorr A.; Tinel H.; Mondritzki T.; Truebel H.; Sandner P.; Stasch J.-P. J. Med. Chem. 2017, 60, 5146-5161: Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure
- Le Roux A.; Blaise E.; Boudreault P.-L.; Comeau C.; Doucet A.; Giarrusso M.; Collin M.-P.; Neubauer T.; Kolling F.; Goeller A.; Seep L.; Tshitenge D. T.; Wittwer M.; Kullmann M.; Hillisch A.; Mittendorf J.; Marsault E. J. Med. Chem. 2020, 63, 6774-6783:Structure-Permeability Relationship of Semipeptidic Macrocycles-Understanding and Optimizing Passive Permeability and Efflux Ratio
Hahn, M. G.; Lampe, T.; El Sheikh, S.; Griebenow, N.; Woltering, E.; Schlemmer, K.-H.; Dietz, L.; Gerisch, M.; Wunder, F.; Becker-Pelster, E.-M.; Mondritzki, T.; Tinel, H.; Knorr, A.; Kern, A.; Lang, D.; Hueser, J.; Schomber, T.; Benardeau, A.; Eitner, F.; Truebel, H.; Mittendorf, J.; Kumar, V.; van den Akker, F.; Schaefer, M.; Geiss, V.; Sandner, P.; Stasch, J.-P. Journal of Medicinal Chemistry 2021, 64, 5323-5344: Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042).
Meibom, D; Meyer, J; von Buehler, C.-J.; Collins, K. D.; Maassen, S.; Gericke, K. M.; Hüser, J.; Mittendorf, J.; Ortega Hernandez, N.; Schamberger, J.; Stampfuss, J.; Straub, A.; Torge, A.; Witowski, N.; Wunder, F. Journal of Medicinal Chemistry 2023, 66, 4659-4670: BAY-6096: A Potent, Selective, and Highly Water-Soluble Adrenergic α2BAntagonist.
Vakalopoulos A.; Wunder F.; Hartung I.V.; Redlich G.; Jautelat R.; Buchgraber P.; Hassfeld J.; Gromov A. V.; Lindner N.; Bierer D.; Gries J.; Kroh W.; Paulsen H.; J.; Mittendorf, Lang D.; Becker-Pelster E.; Brockschnieder D.; Geiss V.; Li V.; Straub A.; Knorr A.; Mondritzki T.; Trübel H.; Raschke M.; Schaefer M.; Thomas D.; Sandner P.; Stasch J.-P.; Follmann M. Journal of Medicinal Chemistry 2023, 66, 7280-7303: New Generation of sGC Stimulators: Discovery of Imidazo[1,2-a]pyridine Carboxamide BAY 1165747 (BAY-747), a Long-Acting Soluble Guanylate Cyclase Stimulator for the Treatment of Resistant Hypertension.
Meibom, D; Wasnaire, P; Beyer K; Broehl A; Cancho-Grande Y; Elowe N; Henninger K; Johannes K; Jungmann N; Krainz T; Lindner N; Maassen S; MacDonald B; Menshykau D; Mittendorf J; Sanchez G; Schaefer M; Stefan E; Torge A; Xing Y; Zubov D; Journal of Medicinal Chemistry 2024, 67, 2907-2940: BAY-9835: Discovery of the First Orally Bioavailable ADAMTS7 Inhibitor.
Vakalopoulos A.; Basting D.; Brechmann M.; Teller H.; Boultadakis Arapinis M.; Straub A.; Mittendorf J.; Meininghaus M.; Müller T.; Nowak-Reppel K.; Schäfer M.; Wittwer M.; Kullmann M.; Terjung C.; Lang D.; Poethko T.; Marquardt T.; Freudenberger T.; Hüser J.; Heckmann M.; Tinel H. Journal of Medicinal Chemistry 2024, 67, 19165-19187: Discovery of BAY 2413555, First Selective Positive Allosteric Modulator of the M2 Receptor to Restore Cardiac Autonomic Balance.
Fürstner C.; Ackerstaff, J.; Meier H.; Straub A.; Mittendorf J.; Schamberger J.; Schäfer M.; Börngen K.; Jörißen H.; Zubov D.; Zimmermann K.; Tersteegen A.; Geiss V.; Hartmann E.; Albrecht-Küpper B.; D´Orleans-Juste P.; Lapointe C.; Vincent L.; Heitmeier S.; Tinel H. Journal of Medicinal Chemistry 2024, DOI: 10.1021/acs.jmedchem.4c01819: Discovery and Preclinical Characterization of Fulacimstat (BAY 1142524), a Potent and Selective Chymase Inhibitor As a New Profibrinolytic Approach for Safe Thrombus Resolution.
- Mittendorf J.; Hartwig W. Eur. Pat. Appl. 1993, EP 529469 A2: Preparation of 2,3-diamino acids from azidomethyldiketopiperazine derivatives.
- Mittendorf J.; Kunisch F.; Plempel M.; Eur. Pat. Appl. 1993, EP 538691 A1: Preparation of aminotetrahydrothiophenecarboxylates as medical fungicides.
- Mittendorf J.; Kunisch F.; Babczinski P.; Plempel M.; Eur. Pat. Appl. 1993, EP 538689 A1: Preparation of 3-amino-2,3-dihydro-6H-pyran-2-carboxylates as medical fungicides.
- Kunisch F.; Mittendorf J,; Plempel M. Eur. Pat. Appl. 1993, EP 538688 A1: Preparation and antimycotic activity of substituted tetrahydrofurans.
- Kunisch F.; Mittendorf J.; Plempel M.; Militzer H.-C. Eur. Pat. Appl. 1993, EP 538692 A1: Preparation and antimycotic activity of partially known substituted pyrrolidines.
- Mittendorf J.; Kunisch F.; Matzke M.; Militzer H.-C.; Endermann R.; Metzger K.; Bremm K.-D.; Plempel M.; Eur. Pat. Appl. 1993, EP 571870 A1: Preparation of 1-amino-2-carboxycyclopentanes as antimycotics and antibacterials.
- Uhr H.; Kunisch F.; Wachtler M.; Kugler M.; Mittendorf J. Ger. Offen. 1995, DE 4403838 A1: Preparation of 1,3,2-benzodithiazole 1-oxides as microbicides.
- Militzer, H.-C.; Matzke M.; Mittendorf J.; Schmidt A.; Ziegelbauer K.; Schoenfeld W. Ger. Offen. 1996, DE 4443890 A1: Antimicrobial cyclohex-4-enecarboxylic acids and their preparation.
- Mittendorf J.; Fey P.; Junge B.; Kaulen J.; van Laak K.; Meier H.; Schohe-Loop R. Eur. Pat. Appl. 1996, EP 716081 A1: Highly selective process for the preparation of enantiomerically pure phenyl-substituted 1,4-dihydropyridine-3,5-dicarboxylic acid derivatives.
- Fey P.; van Laak K.; Mittendorf J. Ger. Offen. 1996, DE 4446337 A1: Preparation of 3-cyanobenzaldehydes.
- Matzke M.; Militzer H.-C.; Mittendorf J.; Kunisch F.; Schmidt A.; Schoenfeld W.; Ziegelbauer K. Eur. Pat. Appl. 1997, EP 754678 A2: Improvement of physiological tolerance of pharmaceutically active beta amino acids.
- Kunisch F.; Matzke M.; Militzer H.-C.; Mittendorf J.; Babczinski P.; Schmidt A.; Schoenfeld W.; Ziegelbauer K. Ger. Offen. 1997, DE 19604225 A1: Condensation of beta amino acids and beta aminocyclohexenoic acids for use as antimicrobial agents.
- Mittendorf J.; Eur. Pat. Appl. 1997, EP 805145 A1: Efficient and highly enantioselective process for the preparation of enantiomerically pure cyclopentane-beta-amino acids.
- Mittendorf J.; Dressel J.; Matzke M.; Franz J.; Spreyer, P.; Voehringer V.; Schuhmacher J.; Friedl A.; Horvath E.; Mauler F.; de Vry J.; Jork R. Ger. Offen. 1998, DE 19706903 A1: Use of agonists of central cannabinoid CB1 receptors in neurodegenerative diseases.
- Mittendorf J.; Dressel J.; Matzke M.; Keldenich J.; Mohrs K.; Raddatz S.; Franz J.; Spreyer, P.; Voehringer V.; Schuhmacher J.; Rock M. H.; Friedl A.; Horvath E.; Mauler F.; de Vry J.; Jork R. Ger. Offen. 1998, DE 19740785 A1: Preparation of arylsulfonamides and related compounds as cannabinoid CB1 and CB2 receptor agonists.
- Mittendorf J.; Dressel J.; Matzke M.; Keldenich J.; Mauler F.; de Vry J.; Franz J.; Spreyer, P.; Voehringer V.; Schuhmacher J.; Rock M. H.; Horvath E.; Friedl A.; Ger. Offen. 2000, DE 19837627 A1: Preparation of alkylsulfonyloxyphenoxyindanylmethanol amino acid esters and related compounds as CB1 and CB2 cannabinoid receptor agonists.
- Mittendorf J.; Dressel J.; Matzke M.; Keldenich J.; Mauler F.; de Vry J.; Franz J.; Spreyer, P.; Voehringer V.; Schuhmacher J.; Rock M. H.; Horvath E.; Friedl A.; Mohrs K.; Raddatz S.; Jork R. Ger. Offen. 2000, DE 19837638 A1: Preparation of aryl trifluorobutylsulfonates as CB1 receptor antagonists.
- Mittendorf J.; Henning R.; Raddatz S.; Schlemmer K.-H., Hiraoka M.; Kadono H.; Mogi M.; Moriwaki T.; Murata T.; Sakakibara S.; Shimada M.; Yoshida N.; Yoshino T. PCT Int. Appl. 2000, WO2000020401 A1: Preparation of bis-benzimidazoles as tryptase inhibitors.
- Haerter M.; Albrecht B.; Gerisch M.; Handke G.; Huetter J.; Jensen A.; Krahn T.; Mittendorf J.; Oehme F.; Schlemmer K.-H.; Steinhagen H. PCT Int. Appl.2002, WO2002006247 A1: Preparation of fused amidoalkyluracils as poly(ADP-ribose) synthetase inhibitors.
- Feurer A.; Bennabi S.; Heckroth H.; Schirok H.; Mittendorf J.; Kast R.; Stasch J.-P.; Gnoth M. J.; Muenter K.; Lang D.; Figueroa Perez S.; Ehmke, H. PCT Int. Appl. 2004, WO20040039796 A1: Preparation of phenylaminopyrimidines as Rho-Kinase II inhibitors for the treatment of cardiovascular diseases.
- Bennabi S.; Heckroth H.; Schirok H.; Mittendorf J.; Kast R.; Stasch J.-P.; Gnoth M. J.; Muenter K.; Lang D.; Figueroa Perez S.; Bauser M.; Feurer A.; Ehmke, H. PCT Int. Appl. 2005, WO2005058891 A1: Preparation of pyrrolopyridinyloxyphenylamides and related compounds as cardiovascular agents.
- Schirok H.; Radtke M.; Mittendorf J.; Kast R.; Stasch J.-P.; Gnoth M. J.; Muenter K.; Lang D.; Figueroa Perez S.; Thutewohl M.; Bennabi S.; Ehmke, H. PCT Int. Appl. 2005, WO2005007790 A1: Preparation of heteroaryloxy-substituted phenylamino pyrimidines as Rho kinase inhibitors.
- Schirok H.; Stasch J.-P.; Kast R.; Muenter K.; Gnoth M. J.; Figueroa Perez S.; Thutewohl M.; Bennabi S.; Radtke M.; Lang D.; Mittendorf J.; Ehmke, H. PCT Int. Appl. 2005, WO2005108397 A1: Preparation of substituted phenylaminopyrimidines for use as cardiovascular agents.
- Schirok H.; Stasch J.-P.; Kast R.; .; Figueroa Perez S.; Muenter K.; Gnoth M. J.; Radtke M.; Lang D.; Mittendorf J. Ger. Offen. 2006, DE 102004060752 A1: Preparation of 4-phenoxy-7-azaindoles as rho kinase II inhibitors.
- Schirok H.; Griebenow N.; Fuerstner C.; Mittendorf J.; Stasch J.-P.; Wunder F.; Schlemmer K.-H.; Heitmeier S.; Stoll F. PCT Int. Appl. 2007, WO2007124854 A1: Fused pyrazole derivatives as cardiovascular agents, their preparation, pharmaceutical compositions, and use in therapy.
- Fuerstner C.; Schirok H.; Griebenow N.; Mittendorf J.; Stasch J.-P.; Wunder F.; PCT Int. Appl. 2007, WO2007128454 A1: Preparation of 3-tetrazolylpyrazolopyridines as cardiovascular agents.
- Schirok H.; Mittendorf J.; Stasch J.-P.; Wunder F.; Stoll F.; Schlemmer K.-H. PCT Int. Appl. 2008, WO2008031513 A1: Azabicyclic derivatives as stimulators of guanylate cyclase, their preparation, pharmaceutical compositions, and use for the treatment of cardiovascular disorders.
- Schirok H.; Mittendorf J.; Stasch J.-P.; Wunder F.; PCT Int. Appl. 2008, WO2008061657 A1: Preparation of imidazo[2,1-c]-1,2,4-triazoles as guanylate cyclase activators for treatment of cardiovascular diseases.
- Straub A.; Suessmeier F.; Wunder F; Stasch J.-P.; Li V. M.-J.; Mittendorf J. PCT Int. Appl. 2010, WO 2010079120 A1: Preparation of fused pyrazoles and imidazoles as cardiovascular agents.
- Follmann M.; Stasch J.-P.; Redlich G.; Ackerstaff J.; Griebenow N.; Kroh W.; Knorr A.; Becker E.-M.; Wunder F.; Li V. M.-J.; Hartmann E.; Mittendorf J.; Schlemmer K.-H.; Jautelat R.; Bierer D. PCT Int. Appl. 2011, WO 2011147809 A1: Substituted 5-fluoro-1H-pyrazolopyridine derivatives as guanylate cyclase inhibitor and their preparation and use in the treatment of cardiovascular diseases.
- Follmann M.; Stasch J.-P.; Redlich G.; Ackerstaff J.; Griebenow N.; Wunder F.; Li V. M.-J.; Mittendorf J.; Jautelat R. PCT Int. Appl. 2012, WO 2012010576 A1: Carbamate-substituted diaminopyrimidines as guanylate cyclase inhibitors and their preparation and use in the treatment of cardiovascular diseases.
- Follmann M.; Stasch J.-P.; Redlich G.; Ackerstaff J.; Griebenow N.; Knorr A.; Wunder F.; Li V. M.-J.; Mittendorf J.; Schlemmer K.-H.; Jautelat R. PCT Int. Appl. 2012, WO 2012059549 A1: Substituted 6-fluoro-1H-pyrazolo[4,3-b]pyridines as guanylate cyclase inhibitors and their preparation and use in the treatment of cardiovascular diseases.
- Hahn M.; Follmann M.; Huebsch W.; Becker E.-M.; Stasch J.-P.; Keldenich J.; Delbeck M.; Tinel H.; Wunder F.; Mittendorf J.; Terebesi I.; Lang D.; Martin R. PCT Int. Appl. 2014, WO 2014012934 A1: Preparation of 5-aminotetrahydroquinoline-2-carboxylic acids for use in treatment and/or prevention of cardiovascular and cardiopulmonary disorders.